卖什么
AI驱动的临床试验。
商业模式拆解
买家：谁掌握预算？
未核实Clinical development and operations heads at biopharma sponsors and CROs.
触发点：什么让他们现在购买？
Slow, costly trials with many protocol amendments; competitive pressure to reach approval first.
工作流：什么输入变成什么输出？
Aika generates protocol, IB and ICF in minutes, simulates and checks feasibility, handles contracts/budgets, site activation, eligibility, regulatory and data in one operating system.
经济账：省了什么，怎么收费？
Enterprise platform; claims 60% cost reduction, 70% faster workflow, 50% fewer protocol amendments.
渠道：怎么接触到客户？
Demo-led ('Book a demo', 'Access Aika'), partnerships and events.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| 2026-02-02 | A 轮 | €43.8M | — | news.google.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.